What precautions should be taken when initiating rifampicin therapy?

Precautions for Rifampicin

Before initiating rifampicin, check baseline liver function tests, renal function, complete blood count, and platelet count, and counsel patients about serious adverse reactions including hepatotoxicity, drug interactions, and the need to double corticosteroid doses if on maintenance therapy. 1, 2

Pre-Treatment Screening Requirements

Mandatory Baseline Testing

• Liver function tests (AST/ALT, bilirubin) - essential before starting treatment 1
• Renal function - particularly if considering combination with streptomycin or ethambutol 1
• Complete blood count and platelet count 2
• Virological tests to exclude coexistent viral hepatitis should be considered 1

Patient Education - Critical Warnings

Patients must be informed about 1, 2:

• Discoloration warning: Rifampicin causes yellow-orange-red-brown discoloration of urine, sweat, tears, saliva, and sputum; soft contact lenses may be permanently stained 2
• Stop medication immediately if fever, malaise, vomiting, jaundice, or unexplained deterioration occur 1
• Seek medical attention for these symptoms before next dose 1

Hepatotoxicity Monitoring - Algorithmic Approach

For Patients WITH Pre-existing Liver Disease

Intensive monitoring required 1:

• Weekly liver function tests for 2 weeks
• Then every 2 weeks for the first 2 months
• Continue until values normalize

For Patients WITHOUT Pre-existing Liver Disease and Normal Baseline LFTs

Symptom-based monitoring 1:

• Routine monitoring NOT required if baseline normal
• Repeat LFTs only if symptoms develop (fever, malaise, vomiting, jaundice)

Managing Elevated Transaminases - Specific Thresholds

If AST/ALT 2-5× normal 1:

• Monitor weekly for 2 weeks, then every 2 weeks until normal
• Continue rifampicin with close monitoring

If AST/ALT ≥5× normal OR bilirubin rises 1:

• STOP rifampicin, isoniazid, and pyrazinamide immediately
• If non-infectious TB and patient stable: wait until LFTs normalize
• If infectious (smear-positive) or unwell: use streptomycin + ethambutol until LFTs normalize

Critical Drug Interactions

Absolutely Contraindicated Combinations

Do NOT coadminister rifampicin with 1, 2:

• Saquinavir/ritonavir - causes severe hepatocellular toxicity 2
• Praziquantel - reduces levels to undetectable 2
• Most protease inhibitors (atazanavir, darunavir, tipranavir, fosamprenavir) - substantial decrease in exposure leading to treatment failure 3, 2

High-Risk Interactions Requiring Dose Adjustments

Corticosteroids 1:

• Double the maintenance corticosteroid dose when starting rifampicin 1
• This is non-negotiable for patients on chronic steroids

Oral contraceptives 1, 2:

• Rifampicin renders hormonal contraceptives ineffective
• Add barrier contraception method 3, 2

Anticoagulants (warfarin) 3, 2:

• May require 2-3 fold warfarin dose increase
• Monitor prothrombin time closely

Methadone 3, 2:

• Marked reduction in serum levels causes withdrawal symptoms
• Anticipate need for dose increase in stable patients

Antiretrovirals 1, 4:

• Rifampicin induces CYP3A4, dramatically reducing protease inhibitor levels
• Three management options: (1) discontinue protease inhibitor temporarily (preferred), (2) omit rifampicin and extend TB treatment to 18 months, or (3) substitute rifabutin for rifampicin 1

Rare but Serious Adverse Reactions

Immunologic Reactions - Intermittent Dosing Risk

Shock, acute renal failure, thrombocytopenic purpura 1:

• Occur rarely, usually with intermittent treatment (twice weekly dosing >600mg)
• If these occur: withdraw rifampicin permanently and do NOT reintroduce 1
• Rifampicin is NOT recommended for intermittent therapy 2

Hemolysis and Acute Kidney Injury

Drug re-exposure carries high risk 5:

• Hemolytic anemia with hemoglobin cast nephropathy can occur
• Most common with interrupted therapy or re-exposure
• Presents with gastrointestinal and flu-like symptoms 1 day to 1 month after re-exposure
• Avoid interrupted rifampicin therapy 2, 5

Special Populations

Pregnancy

• Rifampicin is safe in pregnancy - not teratogenic 1
• Pyridoxine 25 mg/day recommended if combined with isoniazid 6
• Hepatitis risk may increase in peripartum period 6
• Breastfeeding is safe while on rifampicin 1

Renal Disease

• Rifampicin can be given in standard dosage without adjustment 1, 6
• No dose modification needed for dialysis patients 6

Diabetes

• Use with caution - may worsen glucose control 1
• Rifampicin reduces efficacy of sulfonylureas 1, 2

HIV-Positive Patients

• Adverse reactions more common in HIV-positive individuals 1
• Careful management of antiretroviral interactions essential 1, 4

Common Pitfalls to Avoid

1. Forgetting to double corticosteroid doses - leads to adrenal insufficiency 1
2. Not warning about urine discoloration - causes patient alarm and non-adherence 2
3. Intermittent dosing >600mg - dramatically increases risk of severe immunologic reactions 2
4. Restarting rifampicin after interruption without considering hypersensitivity risk 2, 5
5. Combining with protease inhibitors without dose adjustments or alternative strategies 1, 2
6. Routine LFT monitoring in low-risk patients - unnecessary if baseline normal and asymptomatic 1